Last reviewed · How we verify
Control 23-valent PPV
This pneumococcal polysaccharide vaccine stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae, providing protection against pneumococcal disease.
This pneumococcal polysaccharide vaccine stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae, providing protection against pneumococcal disease. Used for Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis) in adults and children ≥2 years of age.
At a glance
| Generic name | Control 23-valent PPV |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Pneumococcal polysaccharide vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (23 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Control 23-valent PPV (pneumococcal polysaccharide vaccine) contains purified capsular polysaccharides from 23 serotypes of Streptococcus pneumoniae. Upon vaccination, these polysaccharide antigens trigger B-cell responses and antibody production, primarily IgG antibodies, which bind to pneumococcal capsules and facilitate opsonization, complement activation, and phagocytic clearance of the bacteria. This provides immunological protection against invasive pneumococcal infections including pneumonia, bacteremia, and meningitis.
Approved indications
- Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis) in adults and children ≥2 years of age
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Myalgia or arthralgia
- Headache
- Fatigue
Key clinical trials
- Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine (PHASE4)
- A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine (PHASE4)
- Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Control 23-valent PPV CI brief — competitive landscape report
- Control 23-valent PPV updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI